Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Dementia with Lewy Bodies

Seelos Therapeutics

NEW YORK, June 9, 2022 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced data demonstrating a statistically significant (p<0.01) 19% downregulation of mRNA and a ~40% reduction of alpha synuclein (α-synuclein) in an in vitro study […]

Stem cells helping patients with Parkinson’s Disease

First FDA approved stem cell trial for Parkinson's Disease

News segment from Houston’s KPRC talking about the first FDA approved stem cell trial that is happening to help patient’s dealing with Parkinson’s Disease. Video Transcript: More than 10 million people worldwide are living with Parkinson’s and 60,000 are in the U.S.. It’s a chronic progressive disease, which means it gets worse over time. But […]

The Impact of T Cells in Neurodegenerative Disease and Regenerative Therapies

The Impact of T Cells in Neurodegenerative Disease and Regenerative Therapies

UCI Sue and Bill Gross Stem Cell Research Center Lecture by Craig Walsh, Ph.D. talking a little bit about the immune system and how particular types of cells of the immune system called T cells; the roles that they play in neurodegenerative diseases, and talk about multiple sclerosis and Alzheimer’s disease. And in particular how […]

2022 WMIF | The Cell Therapy Landscape | CAR-T to Stem Cells

2022 WMIF - The Stem Cell Therapy Landscape

Cell therapies, ranging from CAR-T cells to stem-cell-based approaches, are emerging as a transformative therapeutic modality. Panelists will examine this emerging landscape and discuss a range of key topics. What drives differentiation in this space given the high number of competing technologies? How will the uptake of autologous cell therapies and allogeneic versions evolve? When […]

Study Shows Effectiveness of Merakris’ Wound Care Products

Merakis Logo

RESEARCH TRIANGLE PARK, N.C., June 02, 2022 (GLOBE NEWSWIRE) — A peer-reviewed case study in the May 21 edition of SAGE Open Medical Case Reports highlights the effectiveness of two Merakris Therapeutics wound care products – Dermacyte® Amniotic Wound Care Liquid and Dermacyte® Amniotic Wound Care Matrix – in treating non-healing venous leg ulcers. The […]

Biorep Technologies, Inc. Joins the Tetra Partner Network to Accelerate Research into Stem-Cell Derived Insulin to Cure Diabetes

TetraScience logo

BOSTON, May 31, 2022 /PRNewswire/ — TetraScience, the R&D Data Cloud company, announced today that Biorep Technologies, Inc., the leading provider of scientific instruments that help pharmaceutical companies and leading universities research cures for Type 1 and Type 2 diabetes, has joined the Tetra Partner Network. The partnership builds on a joint deployment of Biorep’s […]

Can Induced Pluripotent Stem Cells Regrow Bones & Teeth?

Dr Hiroshi Egusa using iPSC to grow teeth and bones

Losing your teeth is something that many people face every day. This not only can affect our self-esteem and physical appearance, but also our health and proper digestion of food. Dentures and implants are a common solution to replace teeth, but what if there was the option to actually regrow teeth? iPS cells or induced […]

FUJIFILM Cellular Dynamics Launches Parkinson’s Disease iCell DopaNeurons featuring LRRK2 and GBA Mutations

Fujifilm logo

MADISON, Wis., May 24, 2022 (GLOBE NEWSWIRE) — FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cell (iPSC) products, announced today the launch of Parkinson’s disease (PD) iCell DopaNeurons featuring LRRK2 (G2019S) and GBA (N370S) mutations, which are common PD risk-associated mutations. These PD iCell DopaNeurons were developed […]

TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

TScan Therapeutics Logo

WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, presented two posters and an oral presentation around TScan’s proprietary platform technologies for its solid tumor program at […]